Generation of a Human Conditionally Immortalized Cell-based Multicellular Spheroidal Blood-Brain Barrier Model for Permeability Evaluation of Macromolecules

• Published in: BIO-PROTOCOL Vol. 12; no. 15; p. e4465
• Main Authors: Isogai, Ryuto, Morio, Hanae, Okamoto, Ayaka, Kitamura, Keita, Furihata, Tomomi
• Format: Journal Article
• Language: English
• Published: United States Bio-Protocol, LLC 05.08.2022; Bio-Protocol; Bio-protocol LLC
• Subjects: Biology; Biology (General); Methods; QH301-705.5; Blood-brain barrier; Immortalized cell; Central nervous system; In vitro model; Receptor-mediated transcytosis; Microphysiological systems; Spheroid; Drug development
• ISSN: 2331-8325; 2331-8325
• DOI: 10.21769/bioprotoc.4465

There is an urgent need for the development of brain drug delivery carriers based on middle-sized or macromolecules, to which blood-brain barrier (BBB) models are expected to contribute significantly through evaluation of BBB permeability. As part of efforts to develop such models, we have been working on human conditionally immortalized cell-based multicellular spheroidal BBB models (hiMCS-BBB models), and we herein introduce the model development protocol. Briefly, astrocytes are first seeded in an ultra-low attachment 3D cell culture plate, to make the central core (Day 0). Next, pericytes are added over the core, to form an outer layer (Day 1). Then, brain microvascular endothelial cells are further added to each well, to create the outmost monolayer serving as the BBB (Day 2). Finally, the spheroids cultured for two days (on Day 4) can be used for assays of interest ( ., antibody permeability assays). Neither special equipment nor techniques are required to produce hiMCS-BBB models. Therefore, the protocol presented here will not only facilitate the model sharing among the BBB community but also provide some technical clues contributing to the development of similar MCS-BBB models using other cell sources, such as primary or iPS-derived BBB cells. Graphical abstract.